The drug discovery platform developer will support its growth with new funding from investors including SIG and Legend Capital.
China-based drug discovery platform developer StoneWise has received $100m of series B and B-plus funding from investors including quantitative trading firm Susquehanna International Group, DealStreetAsia reported yesterday. The series B round was led by Legend Capital, the venture capital firm formed by conglomerate Legend Holdings, while fellow VC firm Lightspeed China and Chinese state-backed private…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.